Integrating real-life studies in the global therapeutic research framework

The Lancet Respiratory Medicine

Volumn 1, Issue 10, 2013, Pages

  Roche, Nicolas ^a   Reddel, Helen K ^b   Agusti, Alvar ^c   Bateman, Eric D ^d   Krishnan, Jerry A ^e   Martin, Richard J ^f   Papi, Alberto ^g   Postma, Dirkje ^h   Thomas, Mike ⁱ   Brusselle, Guy ^j   Israel, Elliot ^k   Rand, Cynthia ^l   Chisholm, Alison ^m   Price, David ⁿ  

^a APHP and University Paris Descartes ^*  (France)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^f NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^g UNIVERSITY OF FERRARA   (Italy)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m Respiratory Effectiveness Group   (United Kingdom)

ⁿ UNIVERSITY OF ABERDEEN   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASTHMA; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMORBIDITY; CONCEPTUAL FRAMEWORK; ECOLOGY; HIGH RISK POPULATION; LETTER; MEDICAL RESEARCH; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY CONTROL; RISK FACTOR; STUDY DESIGN; THEORY-PRACTICE RELATIONSHIP; VALIDITY; HUMAN; PRACTICE GUIDELINE; RESPIRATORY TRACT DISEASES; STANDARDS;

BIOMEDICAL RESEARCH; GUIDELINES AS TOPIC; HUMANS; RESPIRATORY TRACT DISEASES;

EID: 84888865885     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70199-1     Document Type: Letter

References (10)

1. Herland K, Akselsen J-P, Skjønsberg OH, et al. How representative are clinical study patients with asthma or COPD for a larger 'real life' population of patients with obstructive lung disease?. Respir Med 2005, 99:11-19.
2. Price D, Chisholm A, van der Molen T, Roche N, Hillyer EV, Bousquet J Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness. Curr Allergy Asthma Rep 2011, 11:526-538.
3. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012, 380:651-659.
4. Pauwels RA, Busse WW, O'Byrne PM, et al. The inhaled Steroid Treatment as Regular Therapy in early asthma (START) study: rationale and design. Control Clin Trials 2001, 22:405-419.
5. Sheikh A, Hurwitz B, Sibbald B, Barnes G, Howe M, Durham S House dust mite barrier bedding for childhood asthma: randomised placebo controlled trial in primary care [ISRCTN63308372]. BMC Fam Pract 2002, 3:12.
6. Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011, 364:1695-1707.
7. Allegra L, Cremonesi G, Girbino G, et al. Real-life prospective study on asthma control in Italy: cross-sectional phase results. Respir Med 2012, 106:205-214. for the PRISMA (PRospectIve Study on asthMA control) Study Group.
8. Colice G, Martin RJ, Israel E, et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. J Allergy Clin Immunol 2013, 132:45-54.e10.
9. Williams B, Noonan G, Reiss TF, et al. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy 2001, 31:845-854.
10. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009, 62:464-475.